Alumis Reports Positive Phase 3 Data With Envudeucitinib

(RTTNews) - Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3. The company said the results reinforced the potential of envudeucitinib to become a leading oral therapy for patients with moderate-to-severe plaque psoriasis. New data showed a 54% Psoriasis Area and Severity Index 100 response rate at Week 48.

Martin Babler, CEO of Alumis, said: "With our fourth-quarter 2026 NDA submission firmly on track, our organization is focused on regulatory execution and building the foundation designed to bring this next-generation therapy to patients."

In pre-market trading on NasdaqGS, Alumis shares are up 3.49 percent to $7.21.

For More Such Health News, visit rttnews.com.